Literature summary for 2.7.10.1 extracted from

Sritana, N.; Auewarakul, C.U.
KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: Two novel mutations and selective occurrence in leukemia subtypes and age groups (2008), Exp. Mol. Pathol., 85, 227-231.

Search for more literature for 2.7.10.1

Application

Application	Comment	Organism
drug development	targeting therapy with specific RTK inhibitors may provide benefits for a subgroup of acute myeloid leukemia patients with favorable chromosomes who also carry selective types of RTK mutations. KIT and FLT3 mutations preferentially exist in distinct clinical and genetic acute myeloid leukemia subtypes, reflecting unique leukemogenetic mechanisms	Homo sapiens

Protein Variants

Protein Variants	Comment	Organism
additional information	FLT3 mutations affect more females than males (80% vs 20%) whereas KIT mutations have no significant effect on the gender distribution. KIT mutations are commonly found in patients aged between 41-60 years whereas FLT3 mutations are frequently found in patients aged between 21-40. Most mutant KIT cases belong to acute myeloid leukemia-M2 subtype (63.6%) whereas most mutant FLT3 cases belong to acute myeloid leukemiaL-M3 subtype (60%). KIT-mutated patients and demonstrate a high expression of myeloid antigens and CD56 lymphoid antigen. FLT3 mutation is coexistent with PML-RARalpha with markedly low or no CD11c and HLA-DR expression	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	Southeast Asian acute myeloid leukemia patients	-

Synonyms

Synonyms	Comment	Organism
FLT3	-	Homo sapiens
KIT	-	Homo sapiens
receptor tyrosine kinase	-	Homo sapiens
RTK	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)